{"disease":{"id":"neoplasm-plasma-cell","name":"neoplasm plasma cell"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04328662","title":"A Study of Ninlaro in Real World Clinical Practice in China","phase":"","overall_status":"COMPLETED","enrollment_count":482,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04537871","title":"Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":350,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07319897","title":"A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03404193","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":235,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02861417","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04090619","title":"Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03246906","title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03141437","title":"Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03017820","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":127,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05011045","title":"Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05053100","title":"Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05101759","title":"Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT03858205","title":"Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06271252","title":"A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"OriCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT04776330","title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04271644","title":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT01251575","title":"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00723099","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT01822509","title":"Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00525057","title":"Dalteparin in Preventing DVT in Participants With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04977024","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"GeoVax, Inc.","has_results":false},{"nct_id":"NCT04439240","title":"Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05581875","title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT04439214","title":"Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01919619","title":"Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04272151","title":"Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03128359","title":"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05280275","title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT05573802","title":"A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT02566304","title":"Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT03192397","title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05972577","title":"Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05336383","title":"Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04309084","title":"Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT02652715","title":"Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03326921","title":"HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT04409314","title":"Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04640779","title":"Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03622788","title":"Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT04681105","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02960646","title":"Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04465760","title":"Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04439305","title":"Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03807063","title":"Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}